期刊文献+

电脉冲化疗对人甲状腺癌裸鼠移植瘤的作用 被引量:2

Effect of Electrochemotherapy on Thyroid Cancer Cell Line TA K in Nude Mice
下载PDF
导出
摘要 [目的]探讨电脉冲化疗对人甲状腺未分化癌裸鼠皮下移植瘤的抗肿瘤效果。[方法]利用人甲状腺未分化癌细胞系TA K进行裸鼠皮下接种 ,建立裸鼠皮下移植瘤模型进行电脉冲化疗实验 ,观察肿瘤局部注射给药和腹腔给药与电脉冲相结合治疗后肿瘤大体和病理组织学变化。[结果]局部注射平阳霉素(PYM)结合电脉冲组与其他实验组比较有明显的抗肿瘤效果 ,其完全缓解率为80 % ,部分缓解率为20 % ,总有效率为100 % ;而腹腔注射PYM结合电脉冲组治疗后肿瘤缩小不足50 % ,肿瘤体积变化与其对照组相比差别不显著 ;对照组、单纯给药组、单纯给予电脉冲组肿瘤继续进展。[结论]利用PYM介导的电脉冲化疗治疗人甲状腺未分化癌裸鼠皮下移植瘤 ,其中局部给药与电脉冲结合效果最好 ;电脉冲化疗无明显局部及全身反应 。 To determine whether pingyangmycin (bleomycin A5) is a better choice for electrochemotherapy on human anaplastic thyroid cancer cell line TA K. Anti tumor efficacy of electrochemotherapy was evaluated on human anaplastic thyroid cancer cell line TA K in vivo.The animal model of ectopic implantation was used.Animals were followed up on periodic tumor volume to determine the response.Histologic change was analysed. A single electrochemotherapy treatment protocol for small tumors resulted in a 100% response rate (CR,80%;PR,20%),tumor progressed in the groups of control,electric pulsed,or drug administration alone.[Conclusion]Electrochemotherapy with bleomycin may have great promise for treatment of human anaplastic thyroid cancer.
出处 《肿瘤学杂志》 CAS 2001年第1期6-8,共3页 Journal of Chinese Oncology
关键词 肿瘤移植 电脉冲化疗 博莱霉素 甲状腺癌 治疗 thyroid neoplasms neoplasm transplantation electrochemotherapy mice,nude neoplasms,experimental bleomycin
  • 相关文献

参考文献2

二级参考文献3

共引文献1

同被引文献34

  • 1孙辉,王金国,付言涛,何尔斯泰.小鼠肌肉内绿色荧光蛋白基因电转染[J].吉林大学学报(医学版),2005,31(2):239-242. 被引量:2
  • 2孙传政,陈福进,曾宗渊,陈艳峰,李秋梨,关中,田慎之.甲状腺未分化癌的治疗和预后[J].中华外科杂志,2006,44(21):1493-1497. 被引量:14
  • 3Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches [Jl. Ann Surg Oncol, 2006, 13(4):453-464.
  • 4Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas [J]. Endocrine Pathology, 2004, 15(4):319-327.
  • 5Santarpia L, El-Naggar AK, Cote GJ, et al. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer[J]. J Clin Endocrinol Metab, 2008, 93(1):278-284.
  • 6Amodeo C, Caglia P, Gandolfo L, et al. Undifferentiated carcinoma of the thyroid [J]. Tumori, 2003, 89 (4 Suppl): 205-206.
  • 7Boltze C, Roessner A, Landt O, et al. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma[J]. Int J Oncol, 2002, 21(5):1151-1154.
  • 8Takano T, Ito Y. Hirokawa M, et al. BRAF V6OOE mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas [J]. Br J Cancer, 2007, 96 (10):1549-1553.
  • 9Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer [J]. Clin Cancer Res, 2007, 13(4): 1161-1170.
  • 10Liu D, Xing M. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways [J]. Thyroid, 2008, 18(8):853-864.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部